Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2013

01.02.2013 | Clinical trial

Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation

verfasst von: Chirag Shah, Thomas B. Lanni, Harkiran Saini, Anish Nanavati, J. Ben Wilkinson, Shahed Badiyan, Frank Vicini

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to analyze the cost-efficacy of multiple accelerated partial-breast irradiation (APBI) techniques compared with whole breast irradiation (WBI) delivered utilizing 3-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT). A previously reported matched-pair analysis consisting of 199 patients receiving WBI and 199 patients receiving interstitial APBI formed the basis of this analysis. Cost analyses included a cost minimization analysis, incremental cost- effectiveness ratio (ICER) analysis, and cost per quality adjusted life year (QALY) analysis. Per 1,000 patients treated, the cost savings with the utilization of APBI compared to WBI IMRT is $14.9 million, $10.9 million, $8.8 million, $5.0 million, and $9.7 million for APBI 3D-CRT, APBI IMRT, APBI single-lumen (SL), APBI multi-lumen (ML), and APBI interstitial, respectively. Per 1,000 patients treated, the cost savings with the utilization of APBI compared to WBI 3D-CRT is $6.0 million, $2.0 million, and $0.7 million for APBI 3D-CRT, APBI IMRT, and APBI interstitial, respectively. The cost per QALY for APBI SL, APBI ML, and APBI interstitial compared with APBI 3D-CRT are $12,273, $66,032, and $546, respectively. When incorporating non-medical costs and cost of recurrences the cost per QALY was $54,698 and $49,009 for APBI ML compared with APBI 3D-CRT. When compared to WBI IMRT, all APBI techniques are cost-effective based on cost minimization, ICER, and QALY analyses. When compared to WBI 3D-CRT, external beam APBI techniques represent a more cost-effective approach based on cost minimization with brachytherapy representing a cost-effective approach based on cost per QALY.
Literatur
1.
Zurück zum Zitat DeSantis C, Siegel R, Bandi P et al (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61:409–418PubMedCrossRef DeSantis C, Siegel R, Bandi P et al (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61:409–418PubMedCrossRef
2.
Zurück zum Zitat Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedCrossRef Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedCrossRef
3.
Zurück zum Zitat Pignol JP, Olivotto I, Rakovitch E et al (2008) A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26:2085–2092PubMedCrossRef Pignol JP, Olivotto I, Rakovitch E et al (2008) A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26:2085–2092PubMedCrossRef
4.
Zurück zum Zitat Donovan E, Bleakley N, Denholm E et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254–264PubMedCrossRef Donovan E, Bleakley N, Denholm E et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254–264PubMedCrossRef
5.
Zurück zum Zitat Shah C, Wobb J, Grills I et al (2012) Use of intensity modulated radiation therapy to reduce acute and chronic toxicities of breast cancer patients treated with traditional and accelerated whole breast irradiation. Pract Radiat Oncol [Epub ahead of print] Shah C, Wobb J, Grills I et al (2012) Use of intensity modulated radiation therapy to reduce acute and chronic toxicities of breast cancer patients treated with traditional and accelerated whole breast irradiation. Pract Radiat Oncol [Epub ahead of print]
6.
Zurück zum Zitat Smith BD, Pan IW, Shih YCT et al (2011) Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798–809PubMedCrossRef Smith BD, Pan IW, Shih YCT et al (2011) Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798–809PubMedCrossRef
7.
Zurück zum Zitat Hattangadi JA, Taback N, Neville B et al (2012) Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline accordance. J Natl Cancer Inst 104:29–41PubMedCrossRef Hattangadi JA, Taback N, Neville B et al (2012) Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline accordance. J Natl Cancer Inst 104:29–41PubMedCrossRef
8.
Zurück zum Zitat Polgar C, Fodor J, Major T et al (2007) Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma-5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 69:694–702PubMedCrossRef Polgar C, Fodor J, Major T et al (2007) Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma-5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 69:694–702PubMedCrossRef
9.
Zurück zum Zitat Shah C, Antonucci JV, Wilkinson JB et al (2011) Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 100:210–214PubMedCrossRef Shah C, Antonucci JV, Wilkinson JB et al (2011) Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 100:210–214PubMedCrossRef
10.
Zurück zum Zitat Suh WW, Pierce LJ, Vicini FA et al (2005) A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys 62:790–796PubMedCrossRef Suh WW, Pierce LJ, Vicini FA et al (2005) A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys 62:790–796PubMedCrossRef
11.
Zurück zum Zitat Tengs TO, Adams ME, Pliskin JS et al (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15:369–390PubMedCrossRef Tengs TO, Adams ME, Pliskin JS et al (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15:369–390PubMedCrossRef
13.
Zurück zum Zitat Lanni T, Keisch M, Shah C et al (2012) A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery. Breast J 2013 Jan 7 [Epub ahead of print] Lanni T, Keisch M, Shah C et al (2012) A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery. Breast J 2013 Jan 7 [Epub ahead of print]
14.
Zurück zum Zitat Stokes ME, Thompson D, Montoya EL et al (2008) Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 11:213–220PubMedCrossRef Stokes ME, Thompson D, Montoya EL et al (2008) Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 11:213–220PubMedCrossRef
15.
Zurück zum Zitat Shah C, Lanni TB Jr, Ghilezan MI et al (2012) Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate risk prostate cancer. Brachytherapy [Epub ahead of print] Shah C, Lanni TB Jr, Ghilezan MI et al (2012) Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate risk prostate cancer. Brachytherapy [Epub ahead of print]
16.
Zurück zum Zitat Bai Y, Ye M, Cao H et al (2012) Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. Breast Cancer Res Treat 136:547–557PubMedCrossRef Bai Y, Ye M, Cao H et al (2012) Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. Breast Cancer Res Treat 136:547–557PubMedCrossRef
17.
Zurück zum Zitat Sher DJ, Wittenberg E, Suh WW et al (2009) Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys 74:440–446PubMedCrossRef Sher DJ, Wittenberg E, Suh WW et al (2009) Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys 74:440–446PubMedCrossRef
18.
Zurück zum Zitat Greenup RA, Camp MS, Taghian AG et al (2012) Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol [Epub ahead of print] Greenup RA, Camp MS, Taghian AG et al (2012) Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol [Epub ahead of print]
19.
Zurück zum Zitat Dragun AE, Pan J, Riley EC et al (2012) Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol [Epub ahead of print] Dragun AE, Pan J, Riley EC et al (2012) Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol [Epub ahead of print]
20.
Zurück zum Zitat Allemani C, Sant M, Weir HK et al (2012) Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer [Epub ahead of print] Allemani C, Sant M, Weir HK et al (2012) Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer [Epub ahead of print]
Metadaten
Titel
Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation
verfasst von
Chirag Shah
Thomas B. Lanni
Harkiran Saini
Anish Nanavati
J. Ben Wilkinson
Shahed Badiyan
Frank Vicini
Publikationsdatum
01.02.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2412-6

Weitere Artikel der Ausgabe 1/2013

Breast Cancer Research and Treatment 1/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.